Empyrean Neuroscience Launches With $22M Series A And Genetic Engineering Platform To Advance Pipeline Of Neuroactive Compounds Targeting Cns Disorders
Empyrean Neuroscience Launches With $22M Series A And Genetic Engineering Platform To Advance Pipeline Of Neuroactive Compounds Targeting Cns Disorders
10/18/22, 10:07 AM
Location
new yorkMoney raised
$22 million
Industry
therapeutics
biotechnology
Round Type
series a
Empyrean Neuroscience, Inc., a leading genetic engineering company dedicated to developing neuroactive compounds to treat neuropsychiatric and neurologic disorders, today announced that it has launched with a $22 million Series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company is founded on a proprietary platform designed to genetically engineer small molecule therapeutics from fungi and plants. Veteran biotech executives Usman “Oz” Azam, M.D., Chief Executive Officer, and Fred Grossman, D.O., FAPA, Chief Medical Officer, lead the company.
Company Info
Location
new york, united states
Additional Info
Empyrean Neuroscience is a genetic engineering company developing a pipeline of neuroactive therapeutics to treat a range of neuropsychiatric and neurologic disorders. Through precision genetic modification, transformation, and regeneration of fungi and plants, the platform allows for the creation of small molecule therapeutics. In addition, the platform enables the discovery of novel small molecules that may exhibit therapeutic properties. The company is based in New York City and Cambridge, UK.